AstraZeneca's Calquence treads on Imbruvica's turf with second phase 3 CLL win
admin 6th June 2019 Uncategorised 0AstraZeneca’s Calquence has been battling it out in mantle cell lymphoma since it won its first approval back in late 2017, but all along, the company has had its eye on another disease: chronic lymphocytic leukemia. And that’s where it’s
read more